Agilent to Buy Stratagene for $246M, CEO Sorge Plans Molecular Dx Spin-Off | GenomeWeb
NEW YORK (GenomeWeb News) — Agilent Technologies plans to acquire Stratagene for around $246 million in cash, the companies said today.
 
Separately, Stratagene CEO Joseph Sorge plans to form a new company that will pay $6.6 million for some of Stratagene’s molecular diagnostics assets.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.